OEWG Kick-Off Meeting Meg Mooney, MD Chief, Clinical Investigations Branch CTEP, DCTD, NCI – March 24, 2010 CTEP & Cooperative Group Plans for OEWG Implementation:

Slides:



Advertisements
Similar presentations
David M. Pollock Medical College of Georgia Discovery-Academia.
Advertisements

Campus Improvement Plans
AUDIT PROGRAM Tammy Neseth NCCTG Compliance Coordinator.
Eastern cooperative oncology group ECOG ITrack Initiative Integrated Trial Development Process March 23, 2010 Donna Marinucci March 23, 2010 Donna Marinucci.
PLENARY SESSION Fall Group Meeting Miami, FL November 13, 2010.
A Blueprint For Clinical Research: Standard Operating Procedures
Guideline for Monitoring of Clinical Trials for Cooperative Groups, CCOP Research Bases, and the Clinical Trials Support Unit (CTSU) Lore Lagrone Program.
ACRIN Presentation Cancer Trials Support Unit Basics September 21, 2011 Martha Hering, RN, CCRP 21 Sept ACRIN Presentation.
NCI Clinical Trials Reporting Program CTRP User Meeting November 2, 2011 Gene Kraus CTRP Program Director.
National Cancer Institute (NCI) Central Institutional Review Board (CIRB) Research Studies UCSF HRPP Submission Process Overview Tuesday, December.
Tracking Protocol Development Timelines Steve Friedman, MHSA Chief, Clinical Trials Operations and Informatics Branch.
CALGB Informational Session June 22, 2007 David Hurd, MD Interim Chair Data Audit Committee.
NCI Clinical Trials Reporting Program CTRP User Meeting May 2, 2012 Gene Kraus CTRP Program Director.
1 Your Skills and Experience Are a Valuable Resource to Your Department and to the City of Houston. We Wish You an Expedited Recovery and Safe Return to.
1 March 2003 ODAC: DOXIL ®, Ovarian Cancer ODAC Discussion on Accelerated Approval March 12-13, 2003 DOXIL ® (doxorubicin HCl liposome injection) Treatment.
NCI Trial Complexity Elements & Scoring Model A Step by Step Overview of Scoring a Cooperative Group Trial Updated April 16, 2009.
Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate.
Carine M. Lenders, M.D., M.S. Medical Director, NFL program Director, Pediatric Nutrition Support Services Research Staff, General Pediatrics Assistant.
NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.
ODAC SCHERING-PLOUGH RESEARCH INSTITUTE 1 Temozolomide Oncology Drug Advisory Committee March 13, 2003 Craig L. Tendler, M.D. Vice President, Oncology.
CTEP, NCI Adverse Event Reporting Programmatic & Workflow Processes Prepared by: Ann Setser May 24, 2010.
Developing Relationships: Cooperative Group Networking Developing Relationships: Cooperative Group Networking Kandie Dempsey, MS, RN, OCN, CCRP Delaware.
Meeting the Challenges of the Changed Economic Environment Annual Conference September 2009 Water Services Training Group 13 th Annual Conference 10 th.
Understanding the Pre-IDE Program: FDA Perspective
CTEP/Cooperative Group/U01/N01 Meeting: Implementation of OEWG Recommendations March 23, 2010 Welcome & Introduction.
PREPARATION FOR A MONITORING VISIT KEMRI-Wellcome Trust Research Programme Version: 4-Nov-2008.
MODULE B: Case Report Forms Jane Fendl & Denise Thwing April 7, Version: Final 07-Apr-2010.
Experimental Cancer Medicine – the future of cancer care Rosie Davies (LECMC RP based at RLUH) Janet Davies (LECMC RP based at CCO)
CTEP Protocol and Information Office (PIO) Overview.
Research: Intramural and Extramural Jacquelyn Goldberg, JD CIRB Review Board Administrator Clinical Investigations Branch, CTEP Division of Cancer Treatment.
Update From FDA: Office of the Commissioner and Center for Drug Evaluation and Research Janet Woodcock, M.D. Acting Deputy Commissioner for Operations.
The SNM Centralized IND & Clinical Trials Network Enabling Implementation Investigational & Approved PET Imaging in Multicenter Clinical Trials George.
NCI Clinical Trials Reporting Program CTRP User Meeting July 6, 2011 Gene Kraus CTRP Program Director.
1 National Cancer Institute Clinical Trial Cooperative Groups Perspectives from the National Surgical Adjuvant Breast and Bowel Project Joyce Mull, MPM.
An agency of the European Union Presented by: Paolo Tomasi Data Safety Monitoring Boards / Data Monitoring Committees in paediatric studies Paolo Tomasi,
SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.
DEPARTMENT OF HEALTH CARE SERVICES
The NCI Central IRB Initiative Third Annual Medical Research Summit Washington, D.C. March 2003.
S&I Standards Organization Engagement & Communication Plan DRAFT Standards Support Team 1 September 2011.
NCI Clinical Trials Reporting Program CTRP User Meeting October 6, 2010.
Return to Contents Preliminary Private Sector M&E experience in the Northern Cape Presentation to Inaugural South African Private Sector HIV and AIDS Monitoring.
1 EMS Fundamentals An Introduction to the EMS Process Roadmap AASHTO EMS Workshop.
CTEP Plans: Consensus Reviews & Templates Andrea Denicoff, MS, RN, ANP Clinical Investigations Branch CTEP, DCTD OEWG Kick-Off Meeting March 23, 2010.
Current Plan for Critical Path Initiative Janet Woodcock, M.D. Acting Deputy Commissioner For Operations November 5, 2004.
How to Start An Industry Sponsored Clinical Trial
Evaluation Plan Steven Clauser, PhD Chief, Outcomes Research Branch Applied Research Program Division of Cancer Control and Population Sciences NCCCP Launch.
The NCI Central IRB Initiative Jacquelyn L. Goldberg, J.D. VA IRB Chair Training April 8, 2004.
11 User Pays User Committee 14th September Agenda  Minutes & Actions from previous meeting  Agency Charging Statement Update  Change Management.
Overview of Critical-Path Implementation Requirements Infrastructure required for successful program launch includes: Emissions & Allowance Tracking System.
CTEP Visiting Physician Externship Coordinator: Igor Espinoza-Delgado, M.D. NCI CTEP Investigational Drug Branch
NCI Clinical Trials Reporting Program CTRP User Meeting June 6, 2012 Gene Kraus CTRP Program Director.
ROAD MAP: Getting a Cancer Study Done at Jefferson Sylvia O’Neill, MD Associate Director of Regulatory Affairs and Quality Assurance Clinical Trials Office.
Radiation Therapy Trials - Quality Assurance:  patient safety  adherence to protocol constraints  uniformity of patient treatments  efficient review.
NCI Clinical Trials Reporting Program CTRP User Meeting May 4, 2011.
NCI Phase III Treatment Portfolio in Prostate Cancer: Opportunities for Embedding Surrogate Endpoint Questions Alison Martin, M.D. Cancer Therapy Evaluation.
EXCEPTION FROM INFORMED CONSENT IN CPR DEVICE TRIALS: PROTECTION OF PATIENTS’ RIGHTS Circulatory System Devices Panel Meeting September 21, 2004 Elisa.
1 MARCH 2012 Regulatory Documents & the CTSU.
Opening An ETCTN Study at Your Site August Scope of this Presentation  This presentation applies to all sites which will be participating on.
11 Radiation Therapy Oncology Group Clinical Trials Administration Sharon Hartson Stine, Director Group Administrator.
ROAD MAP: Getting a Cancer Study Done at Jefferson Meghan Wakefield,RN,CCRP Senior Director of Clinical Trials Office Clinical Research Organization.
Christine Yalda, J.D., Ph.D. Chair, Human Research Review Committee Grand Valley State University.
Rare Diseases Clinical Research Network Data Management and Coordinating Center (RDCRN DMCC) Rosalie Holland LDN Investigator Meeting at WORLDSymposium.
S1400 Revisions #4/5 Training Slides
AACR Genomics In Clinical Medicine Think Tank
Duke Surgery Research Training Fellowship
Business Practices Subcommittee Update
Suzanne M. Sensabaugh, MS, MBA
Clinical Trial Development: RA’s Role, OEWG, and IRB Submissions Martha Heckel Protocol Associate, ACRIN Dept. of Protocol Development & Regulatory.
Clinical Trial Development: NRG Processes and NCI Requirements
Clinical Trial Development: NRG Processes and NCI Requirements
Presentation transcript:

OEWG Kick-Off Meeting Meg Mooney, MD Chief, Clinical Investigations Branch CTEP, DCTD, NCI – March 24, 2010 CTEP & Cooperative Group Plans for OEWG Implementation: Group Treatment Trials

Overview of CTEP/Group Implementation Plan Funding for Cooperative Group Action Plans – RAPID Establishment of Standing Working Group with Cooperative Group Representatives Concepts, SCs & Consensus Evaluations, CTEP Protocol Consensus Reviews How Do We Set Up a Protocol Timeline that Prioritizes Key Activities? How & When Do We Include Industry Representatives? How Do We Define Allowable Time-Outs? Other Issues?

RaPID – Re-engineering Protocol Implementation and Development All Cooperative Groups have approved funding plans – Each Group’s plan is unique but most have received support for protocol coordinators, officers, and/or medical writers – Most have also received support for IT tools to coordinate Group work – Funding to be awarded in April 2010 Previous ARRA funding provided via ADOPT for IT projects to facilitate rapid protocol development and data management

Standing Working Group for Implementation Establishment of Working Group to discuss & monitor process with recommendations for changes and adjustments Representation from each Cooperative Group  ACOSOG – Susan Budinger  ACRIN – Charlie Apgar  CALGB – Kathy Karas  COG – TBD  ECOG – Jean MacDonald  GOG – Kia Neff  NCCTG – Aimee Tillman  NCIC-CTG – Anna Sudura  NSABP – Walt Cronin  RTOG – Wilma Hoffman  SWOG –Dana Sparks

Concepts, SC / Consensus Evaluations, Protocol Consensus Reviews for Group Trials Specific Issues: ? Page Limit for Concepts (5 to 7 page limit) Schedule for Conference Calls for Concepts that are given a status of “Pending” - Need for set dates/times given # of SCs and need for calls within business hours Concept Consensus Evaluation from SCs are usually all major issues; however, recommendations for secondary objectives (e.g., QOL, correlative science) if not essential components will be recommendations at this stage Protocol Consensus Reviews: CTEP template to be used; potential benefit of comments placed directly into protocol document (?)

How Do We Set Up a Protocol Timeline that Prioritizes Key Activities? Specific Issues: Ongoing Conference Calls – especially for Phase 3 studies? What are the essential elements from Group perspective? Is it possible to compartmentalize certain components, especially secondary endpoints (even defer to amendments after activation if they cannot be accomplished in the targeted timeline)

How Do We Define Allowable Time-Outs? Specific Issues: Already defined: – FDA Review for Phase 3 Registration Trials (as well as early phase clinical trials, as needed) – Industry Review and Approval & Drug Commitment – IRB Review and Approval – Drug Supply Availability Possible Additional “Allowable” Timeouts: – BIQSFP application for an “integral” marker if submitted prior to concept approval – CTSU preparation for opening trial on menu (OPEN) – Other (what do Groups see as possible “allowable” time-outs?) Post-meeting update: IRB review and CTSU placement are no longer considered time-outs. Please see the Time-Out SOP for what constitutes a time-out.

OEWG Kick-Off Meeting Steve Friedman & Meg Mooney, MD Chief, Clinical Investigations Branch CTEP, DCTD, NCI – March 24, 2010 Timeline Tracking (Implementation and Management of Timeouts)

Timeline Tracking - Discussion What Do We Need to Know/Collect from Groups during the Protocol Development Process (Additions to Tracking?) especially with respect to current status of document & reasons for delays? What Type of “Reminder” Systems / Processes Do We Need? GENERAL DISCUSSION Other Issues & Next Steps?